0HI3 Stock Overview Develops medicines for the treatment of intractable diseases in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Arrowhead Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Arrowhead Pharmaceuticals Historical stock prices Current Share Price US$19.50 52 Week High US$39.79 52 Week Low US$17.24 Beta 0.93 1 Month Change 5.87% 3 Month Change -0.32% 1 Year Change -35.81% 3 Year Change -70.90% 5 Year Change -69.81% Change since IPO 218.56%
Recent News & Updates
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Dec 24
CEO, President & Director recently sold US$567k worth of stock Dec 22
Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases Dec 11
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity Dec 03
New minor risk - Revenue size Nov 27
Full year 2024 earnings released: US$4.82 loss per share (vs US$1.92 loss in FY 2023) Nov 27 See more updates
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Dec 24
CEO, President & Director recently sold US$567k worth of stock Dec 22
Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases Dec 11
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity Dec 03
New minor risk - Revenue size Nov 27
Full year 2024 earnings released: US$4.82 loss per share (vs US$1.92 loss in FY 2023) Nov 27
Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors Nov 26 Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
New major risk - Financial position Sep 05
Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Sep 03
Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies Aug 15
New minor risk - Financial position Aug 09
Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023) Aug 09
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial Jun 26
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome Jun 05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma May 22
Now 22% undervalued after recent price drop May 11
Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023) May 10
Now 23% undervalued after recent price drop Apr 24
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease Apr 24
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo Apr 09
Chief Financial Officer recently sold US$1.4m worth of stock Mar 11
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy Mar 08
Now 27% overvalued after recent price rise Mar 01
First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023) Feb 07
Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024 Jan 27
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024 Jan 22
Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million. Jan 05
New major risk - Financial position Dec 06
New major risk - Financial position Nov 30
Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022) Nov 30
Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy Nov 29
Chief Medical Officer recently sold US$567k worth of stock Nov 23
Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 Nov 15
New minor risk - Share price stability Oct 05
New major risk - Revenue and earnings growth Sep 23
Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022) Aug 08
New minor risk - Insider selling Jul 03
Chief Financial Officer recently sold US$543k worth of stock Jul 02
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1 Jun 28
Chairman of the Board recently sold US$266k worth of stock May 10 May 03
Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022) May 03 Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022) Feb 07
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis Feb 03
Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023 Jan 31
Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics. Jan 22
Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Jan 10
Insufficient new directors Jan 01
Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study Dec 22
No longer forecast to breakeven Dec 01
Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline Nov 08
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3 Oct 12
Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021) Aug 05
Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer Jul 21
Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE Jul 06
Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine Jun 28
Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021) May 11
Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors May 03
Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia Apr 27
Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia Feb 25
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases Feb 19
Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 Feb 18
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 04
Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome Jan 13
Independent Director recently sold US$291k worth of stock Jan 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Nov 23
Chairman of the Board recently sold US$326k worth of stock Sep 14
Chief Commercial Officer James Hassard has left the company Sep 02
Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020) Aug 08
Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study Jul 03
Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia Jul 01
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress Jun 26
Chief Commercial Officer recently sold US$323k worth of stock Jun 25
Arrowhead Pharmaceuticals, Inc. Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH At EASL International Liver Congress Jun 24
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia Jun 04
Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.20 loss in 2Q 2020) May 06
Arrowhead Pharmaceuticals Inc. Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease Apr 29
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia Mar 03
Chairman of the Board recently sold US$100k worth of stock Feb 27
First quarter 2021 earnings released: US$0.20 loss per share (vs US$0.028 loss in 1Q 2020) Feb 06
Revenue misses expectations Feb 06
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia Jan 26
Chief Financial Officer recently sold US$1.1m worth of stock Jan 20
Chairman of the Board recently sold US$759k worth of stock Dec 22 Shareholder Returns 0HI3 GB Biotechs GB Market 7D -12.4% -5.0% -1.9% 1Y -35.8% -24.4% 2.6%
See full shareholder returns
Return vs Industry: 0HI3 underperformed the UK Biotechs industry which returned -24.4% over the past year.
Return vs Market: 0HI3 underperformed the UK Market which returned 2.6% over the past year.
Price Volatility Is 0HI3's price volatile compared to industry and market? 0HI3 volatility 0HI3 Average Weekly Movement 10.3% Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0HI3's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HI3's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials.
Show more Arrowhead Pharmaceuticals, Inc. Fundamentals Summary How do Arrowhead Pharmaceuticals's earnings and revenue compare to its market cap? 0HI3 fundamental statistics Market cap US$2.44b Earnings (TTM ) -US$599.49m Revenue (TTM ) US$3.55m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0HI3 income statement (TTM ) Revenue US$3.55m Cost of Revenue US$0 Gross Profit US$3.55m Other Expenses US$603.04m Earnings -US$599.49m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.82 Gross Margin 100.00% Net Profit Margin -16,882.37% Debt/Equity Ratio 384.5%
How did 0HI3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 01:16 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Arrowhead Pharmaceuticals, Inc. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Ying Huang Barclays Jason Matthew Gerberry BofA Global Research
Show 26 more analysts 